ReviewEuropean child & adolescent psychiatry2026
Attention deficit hyperactivity disorder (ADHD) and premature mortality: A narrative review of the literature.
Review in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Attention-deficit hyperactivity disorder (ADHD) is associated with a higher risk of premature mortality compared to the general population, although reported risks vary. The aim of this paper was to review studies that have examined associations between premature mortality and ADHD and consider factors that could explain variation in risk estimates. A literature search was carried out using online databases (PMC, OVID, and Scopus library) to identify relevant articles. We then considered: sample ascertainment, sample size, method of diagnosing ADHD and age at diagnosis, sex, age range for mortality data, hazard ratio/ mortality rate ratio (95% confidence interval), sample size, and cause of death, as factors that could explain variation in risk estimates. We focus on nine papers that report risk of all-cause mortality in population samples via hazard ratios, odds ratios, and mortality ratios, which varied from 1.07 to 4.44. Higher risk estimates were found in studies that followed up to older ages and among individuals who were female, diagnosed with ADHD later, and had psychiatric comorbidity. Most follow up found non-natural causes (e.g. suicide, accidents) to be the most prevalent cause of death but studies with longer follow up suggested that non-natural causes may be more important in older individuals. Evidence suggests that ADHD medication reduces the risk of premature mortality but findings are clearer for stimulant than for non-stimulant medication. Clinicians need to be aware that females with ADHD, those with a delayed ADHD diagnosis and who show psychiatric comorbidity are at highest risk of premature mortality. However prescribing ADHD medication may reduce this risk.
Indexed as
Identifiers
42560514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.